Quick Answer
Humacyte, Inc. reported Total Revenue of $2.04 million for fiscal year 2025.
Humacyte, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.04M | $0.00 | — | — | — | — |
| Revenue (ASC 606) | $2.04M | $0.00 | — | — | — | — |
| Net Income | -$40.83M +72.5% |
-$148.70M -34.2% |
-$110.78M -825.8% |
-$11.96M +54.8% |
-$26.48M +60.2% |
-$66.52M |
| Diluted EPS | -$0.26 +79.4% |
-$1.26 -17.8% |
-$1.07 -791.7% |
-$0.12 +81.8% |
-$0.66 +94.3% |
-$11.54 |
| Total Assets | $116.37M -15.6% |
$137.87M +7.5% |
$128.22M -37.2% |
$204.30M -28.7% |
$286.53M +168.6% |
$106.69M |
| Cash and Equivalents | $50.50M +12.4% |
$44.94M -44.1% |
$80.45M -46.3% |
$149.77M -31.1% |
$217.50M +444.7% |
$39.93M |
| Long-Term Debt | $35.44M | $0.00 | — | — | — | — |
| Stockholders Equity | $3.11M +105.9% |
-$52.67M -488.8% |
$13.55M -88.4% |
$116.93M -4.3% |
$122.17M +134.9% |
-$350.32M -21.3% |
| R&D Expense | $69.30M -21.8% |
$88.60M +15.7% |
$76.55M +21.0% |
$63.26M +3.1% |
$61.34M +13.4% |
$54.08M |
| Operating Income | -$108.14M +5.5% |
-$114.40M -14.3% |
-$100.05M -18.3% |
-$84.58M -4.1% |
-$81.21M -25.7% |
-$64.60M |
| Shares Outstanding | 193.00M +48.4% |
130.03M +25.4% |
103.67M +0.4% |
103.23M +0.2% |
103.00M +1669.1% |
5.82M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $753.0K | — | +150.2% |
| Revenue (ASC 606) | September 30, 2025 | $753.0K | — | +150.2% |
| Net Income | September 30, 2025 | -$17.51M | +55.3% | +53.5% |
| Diluted EPS | September 30, 2025 | -$0.11 | +66.7% | +54.2% |
| Total Assets | September 30, 2025 | $91.51M | -20.3% | -34.1% |
| Cash and Equivalents | September 30, 2025 | $19.49M | -5.3% | -48.8% |
| Stockholders Equity | September 30, 2025 | -$4.75M | +92.5% | -217.3% |
| R&D Expense | September 30, 2025 | $17.27M | -24.7% | -21.5% |
| Operating Income | September 30, 2025 | -$24.39M | +19.3% | +18.0% |
| Shares Outstanding | September 30, 2025 | 158.84M | +32.5% | +1.6% |
- Humacyte, Inc. reported Total Revenue of $2.04 million for fiscal year 2025.
- Humacyte, Inc. reported Revenue (ASC 606) of $2.04 million for fiscal year 2025.
- Humacyte, Inc. reported Net Income of -$40.83 million for fiscal year 2025.
- Humacyte, Inc. showed an increase of +72.5% in Net Income compared to the prior fiscal year.
- Humacyte, Inc. reported Diluted EPS of $0.26 per share (loss) for fiscal year 2025.
- Humacyte, Inc. showed an increase of +79.4% in Diluted EPS compared to the prior fiscal year.
- Humacyte, Inc. reported Total Assets of $116.37 million for fiscal year 2025.
- Humacyte, Inc. showed a decrease of -15.6% in Total Assets compared to the prior fiscal year.
- Humacyte, Inc. reported Cash and Equivalents of $50.50 million for fiscal year 2025.
- Humacyte, Inc. showed an increase of +12.4% in Cash and Equivalents compared to the prior fiscal year.
- Humacyte, Inc. reported Long-Term Debt of $35.44 million for fiscal year 2025.
- Humacyte, Inc. reported Stockholders Equity of $3.11 million for fiscal year 2025.
- Humacyte, Inc. showed an increase of +105.9% in Stockholders Equity compared to the prior fiscal year.
- Humacyte, Inc. reported R&D Expense of $69.30 million for fiscal year 2025.
- Humacyte, Inc. showed a decrease of -21.8% in R&D Expense compared to the prior fiscal year.
- Humacyte, Inc. reported Operating Income of -$108.14 million for fiscal year 2025.
- Humacyte, Inc. showed an increase of +5.5% in Operating Income compared to the prior fiscal year.
- Humacyte, Inc. reported Shares Outstanding of 193.00 million shares for fiscal year 2025.
- Humacyte, Inc. showed an increase of +48.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: